GlassScriptPhysician profile
Antonio L Carro
NPI 1003825720
$4,132.09
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $901 · 2021: $335 · 2022: $794 · 2023: $965 · 2024: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.40 | 2019-2024 | Linzess, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $471.49 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $430.69 | 2019-2023 | |
| Lilly USA, LLC | $363.25 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $246.24 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $210.45 | 2019-2024 | Belsomra, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.48 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $145.38 | 2019-2023 | Xarelto |
| Pfizer INC. | $121.89 | 2019-2020 | |
| Medicure Pharma INC. | $120.96 | 2020 | |
| Nestle Healthcare Nutrition INC. | $115.36 | 2022 | |
| Agios Pharmaceuticals, INC. | $112.33 | 2022-2023 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $91.67 | 2019-2020 | |
| Amgen INC. | $84.95 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $78.95 | 2022-2023 | Quviviq |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Carro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.